(73) reported that the specific T-cell response to the clonal tumor antigen encoded by EGFR-driven mutation was successfully identified in a patient with advanced EGFR-mutant NSCLC who benefited from ICIs after developing TKIs resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.